Transgene (Euronext Paris: TNG), a biotech company that designs
and develops virus-based immunotherapies for the treatment of
cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT, network
and AI technologies and BostonGene Corporation (BostonGene), a
leading company in AI-based molecular and immune profiling, today
announced the expansion of their collaboration for the randomized
Phase I/II trial of TG4050, an individualized therapeutic vaccine
for patients with head and neck cancers.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240305404031/en/
BostonGene is partnering with NEC and Transgene to continue
performing tumor molecular profiling and microenvironment analysis
and provide high-throughput sequencing services. The partnership
with BostonGene will enable fast turnaround of next-generation
sequencing (NGS) data, and sophisticated analytics will enable
comprehensive profiling of patient immune contexture.
TG4050, a personalized immunotherapy designed to stimulate the
immune system of patients to induce a neoantigen specific T-cell
response that can recognize and destroy tumor cells, is based on
Transgene’s myvac® platform and powered by NEC’s AI-driven
Neoantigen Prediction System.
“Our collaboration with BostonGene has provided in-depth
information on patient phenotypes in the Phase I trial. It has
allowed us to understand the baseline status of our patients and
how the tumor micro-environment (TME) might evolve following
treatment,” said Dr. Alessandro Riva, Chairman and CEO of
Transgene.
“The combined expertise of Transgene, NEC and BostonGene will
continue to provide a streamlined pipeline for the timely delivery
of patient-tailored vaccines as well as data to guide the future
development of new personalized treatment options, elevating the
standard of care for head and neck cancer patients,” said Masamitsu
Kitase, Corporate SVP and Head of the Healthcare and Life Sciences
Division at NEC Corporation.
“We are committed to supporting Transgene and NEC as they
advance these clinical trials,” said Nathan Fowler, MD, Chief
Medical Officer at BostonGene. “Our molecular and immune profiling
techniques comprehensively analyze the tumor, microenvironment, and
immune system to identify key predictors of response to TG4050,
ultimately improving treatment outcomes.”
***
About myvac® myvac® is a viral vector (MVA – Modified
Vaccinia Ankara) based, individualized immunotherapy platform that
has been developed by Transgene to target solid tumors.
myvac®-derived products are designed to stimulate the patient’s
immune system to recognize and destroy tumors using their own
cancer specific genetic mutations. Transgene has set up an
innovative network that combines bioengineering, digital
transformation, established vectorization know-how and unique
manufacturing capabilities. Transgene has been awarded “Investment
for the Future” funding from Bpifrance for the development of its
platform myvac®. TG4050 is the first myvac®-derived product being
evaluated in clinical trials.
Click here to watch a short video on myvac®.
About TG4050 TG4050 is an individualized immunotherapy
being developed for solid tumors that is based on Transgene’s
myvac® technology and powered by NEC’s longstanding artificial
intelligence (AI) and machine learning (ML) expertise. This
virus-based therapeutic vaccine encodes neoantigens
(patient-specific mutations) identified and selected by NEC’s
Neoantigen Prediction System. The prediction system is based on
more than two decades of expertise in AI and has been trained on
proprietary data allowing it to accurately prioritize and select
the most immunogenic sequences.
TG4050 is designed to stimulate the immune system of patients in
order to induce a T-cell response that is able to recognize and
destroy tumor cells based on their own neoantigens. This
individualized immunotherapy is developed and produced for each
patient.
Initial immunological and clinical data from the ongoing Phase I
trial in the adjuvant treatment of HPV-negative head and neck
cancers were presented at several conferences in 2023 and are very
encouraging.
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on
designing and developing targeted immunotherapies for the treatment
of cancer. Transgene’s programs utilize viral vector technology
with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of
therapeutic vaccines and oncolytic viruses: TG4050, the first
individualized therapeutic vaccine based on the myvac® platform,
TG4001 for the treatment of HPV-positive cancers, as well as BT-001
and TG6050, two oncolytic viruses based on the Invir.IO® viral
backbone.
With Transgene’s myvac® platform, therapeutic vaccination enters
the field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at:
www.transgene.fr Follow us on social media: X (formerly Twitter):
@TransgeneSA – LinkedIn: @Transgene
About NEC Corporation NEC Corporation has established itself as
a leader in the integration of IT and network technologies while
promoting the brand statement of “Orchestrating a brighter world.”
NEC enables businesses and communities to adapt to rapid changes
taking place in both society and the market as it provides for the
social values of safety, security, fairness and efficiency to
promote a more sustainable world where everyone has the chance to
reach their full potential. For more information, visit NEC at
https://www.nec.com and NEC’s AI Drug Development Business at
https://www.nec.com/en/global/solutions/ai-drug/.
Transgene disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
About BostonGene Corporation BostonGene has a mission to
provide transformative, AI-integrated molecular analytics and
biomarker discovery for precision matching of therapies to improve
the lives of patients living with cancer and other immune-related
diseases. BostonGene’s service model provides customized client
solutions using a multi-omic approach prioritized for real-world
impact, including optimized standard-of-care therapies, accelerated
research and cost-effective, measurable results. BostonGene’s tests
reveal key drivers of each patient’s unique disease profile,
including an in-depth profile of the immune microenvironment,
actionable mutations, biomarkers of response to diverse therapies,
and recommended therapies. Through these comprehensive analyses,
BostonGene’s tests generate a personalized roadmap for therapeutic
decision-making for each patient. For more information, visit
BostonGene at http://www.BostonGene.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305404031/en/
Media Contacts:
Transgene: Lucie Larguier Director of Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: MEDiSTRAVA Consulting Frazer Hall/Sylvie
Berrebi +44 (0)203 928 6900 transgene@medistrava.com
NEC Joseph Jasper +81-3-3798-6511 j-jasper@nec.com
BostonGene Erin O’Reilly +1-617-283-2285
Erin.Oreilly@BostonGene.com
Transgene (EU:TNG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Transgene (EU:TNG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024